Metabolites distinguishing visceral fat obesity and atherogenic traits in individuals with overweight

To screen the metabolomes of both overweight subjects with low visceral fat area (LFO) and high visceral fat area (HFO) to identify potential metabolites that are associated with the different metabolic characteristics.

[1]  C Bachmann,et al.  Age-related reference values for urinary organic acids in a healthy Turkish pediatric population. , 1994, Clinical chemistry.

[2]  J. Fevery,et al.  Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. , 1996, Gastroenterology.

[3]  Piero Rinaldo,et al.  Fatty acid oxidation disorders. , 2002, Annual review of physiology.

[4]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[5]  E. Gabazza,et al.  Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. , 2003, Diabetes care.

[6]  Remi Rabasa-Lhoret,et al.  Metabolic and body composition factors in subgroups of obesity: what do we know? , 2004, The Journal of clinical endocrinology and metabolism.

[7]  S. Kiechl,et al.  Screening for Carnitine Palmitoyltransferase II Deficiency by Tandem Mass Spectrometry , 2002, Journal of Inherited Metabolic Disease.

[8]  Remi Rabasa-Lhoret,et al.  The metabolically healthy but obese individual presents a favorable inflammation profile. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[10]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[11]  D. Muoio,et al.  Lipid-induced metabolic dysfunction in skeletal muscle. , 2007, Novartis Foundation symposium.

[12]  A. Karelis,et al.  Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. , 2008, Diabetes & metabolism.

[13]  K. Reynolds,et al.  The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). , 2008, Archives of internal medicine.

[14]  H. Superko,et al.  Is it LDL particle size or number that correlates with risk for cardiovascular disease? , 2008, Current atherosclerosis reports.

[15]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[16]  P. Whincup,et al.  HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. , 2009, Atherosclerosis.

[17]  F. Toledo,et al.  Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity , 2010, Obesity.

[18]  William O Richards,et al.  Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. , 2010, Gastroenterology.

[19]  Nguyen Dang Hung,et al.  Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn-1 Position is Anti-inflammatory , 2010, Lipids.

[20]  C. Bouchard,et al.  Abdominal obesity and mortality: The Pennington Center Longitudinal Study , 2012, Nutrition & Diabetes.

[21]  M. Hey‐Mogensen,et al.  Obesity augments the age‐induced increase in mitochondrial capacity for H2O2 release in Zucker fatty rats , 2012, Acta physiologica.

[22]  A. Evans,et al.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. , 2012, Clinical pharmacokinetics.

[23]  David S. Wishart,et al.  MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis , 2012, Nucleic Acids Res..

[24]  A. Evans,et al.  Carnitine and Acylcarnitines , 2012, Clinical Pharmacokinetics.

[25]  E. Stamatakis,et al.  Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. , 2012, The Journal of clinical endocrinology and metabolism.

[26]  J. Després,et al.  Body Fat Distribution and Risk of Cardiovascular Disease: An Update , 2012, Circulation.

[27]  C. Phillips.  Metabolically healthy obesity: Definitions, determinants and clinical implications , 2013, Reviews in Endocrine and Metabolic Disorders.

[28]  T. Okahisa,et al.  Visceral fat predominance is associated with non‐alcoholic fatty liver disease in Japanese women with metabolic syndrome , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  N. Stefan,et al.  Metabolic Signatures of Cultured Human Adipocytes from Metabolically Healthy versus Unhealthy Obese Individuals , 2014, PloS one.

[30]  M Borle Rajiv,et al.  Textbook of Oral and Maxillofacial Surgery , 2014 .

[31]  Sungha Park,et al.  Metabolomic approaches to the normal aging process , 2014, Metabolomics.

[32]  Young-Tae Ahn,et al.  Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. , 2015, Atherosclerosis.

[33]  Christopher,et al.  Diabetes and Cardiovascular Disease Outcomes in theMetabolically Healthy Obese Phenotype A cohort study , 2015 .

[34]  S. Adams,et al.  Acylcarnitines—old actors auditioning for new roles in metabolic physiology , 2015, Nature Reviews Endocrinology.

[35]  D. Mutch,et al.  Metabolomics Reveals Metabolically Healthy and Unhealthy Obese Individuals Differ in their Response to a Caloric Challenge , 2015, PloS one.

[36]  Y. Tsai,et al.  The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity , 2015, International Journal of Obesity.

[37]  S. Martínez-Hervás,et al.  Unsaturated Oral Fat Load Test Improves Glycemia, Insulinemia and Oxidative Stress Status in Nondiabetic Subjects with Abdominal Obesity , 2016, PloS one.

[38]  M. Calvani,et al.  New obesity classification criteria as a tool for bariatric surgery indication. , 2016, World journal of gastroenterology.

[39]  Diederik F Van Wijk,et al.  C‐Reactive Protein Identifies Low‐Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer–Norfolk Prospective Population Study , 2016, Journal of the American Heart Association.